Abstract Details

Title Long-Term Impact of Fremanezumab on Headache-Related Disability and Quality of Life in Patients Who Reverted From a Chronic to an Episodic Migraine Classification

Topic Headache

Presentation(s) P1 - Poster Session 1 (5:30 PM-6:30 PM)

Poster/Presentation
Number 13-022

Objective

To evaluate the long-term effects of fremanezumab on headache-related disability and quality of life (QoL) in adults with chronic migraine (CM) who reverted to an episodic migraine (EM) classification.

Background Patients with CM experience greater reduction in QoL than patients with EM. Fremanezumab, a fully humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP), is approved in the US for the preventive treatment of migraine. In a 12-week Phase 3 trial, significantly more fremanezumab-treated patients than those given placebo reverted from CM to an EM classification.

Design/Methods In this 52-week, multicenter, randomized, double-blind, parallel-group study, patients with CM received either subcutaneous fremanezumab monthly (225 mg every month; starting dose of 675 mg) or quarterly (675 mg every 3 months). This post hoc analysis evaluated the effect of fremanezumab on headache-related disability (assessed with the six-Item Headache Impact Test [HIT-6]) and QoL (Migraine-specific Quality of Life [MSQoL]) in a subgroup of patients who reverted from CM to EM, defined as ≥15 monthly headache days at baseline and <15 headache days at Month 12.

Results Of 813 patients with CM at baseline, 548 reverted to EM. In this subgroup, the mean change in HIT-6 score from baseline to Month 6 was –8.4 for quarterly dosing and –9.6 for monthly dosing; from baseline to Month 12, it was –9.7 for quarterly dosing and –10.3 for monthly dosing. The mean change in MSQoL scores from baseline to Month 6 was 27.1 for quarterly dosing and 27.8 for monthly dosing; from baseline to Month 12, it was 30.8 for quarterly dosing and 31.4 for monthly dosing.

Conclusions Among patients who reverted from a CM to an EM classification, improvement in headache-related disability at Month 6 was maintained through Month 12. QoL also improved progressively through Month 12 with long-term fremanezumab treatment.

Authors/Disclosures
Jessica Ailani, MD, FAAN (Medstar Georgetown Neurology) PRESENTER	Dr. Ailani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Abbvie. Dr. Ailani has received personal compensation in the range of $0-$499 for serving as a Consultant for Eli Lilly. Dr. Ailani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Ailani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ipsen. Dr. Ailani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Merz. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Aspya. Dr. Ailani has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axsome. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bausch. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amneal. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Satsuma. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Kallyope. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Self Magazine. The institution of Dr. Ailani has received research support from Ipsen. The institution of Dr. Ailani has received research support from Parema. The institution of Dr. Ailani has received research support from Lundbeck. The institution of Dr. Ailani has received research support from Merz. The institution of Dr. Ailani has received research support from Pfizer. Dr. Ailani has received research support from Mi-Helper. The institution of Dr. Ailani has received research support from ShiraTronic. Dr. Ailani has a non-compensated relationship as a Executive Board Member with American Headache Society that is relevant to AAN interests or activities.
Joshua M. Cohen, MD	No disclosure on file
Marianna S. Yugrakh, MD (Columbia University)	The institution of Dr. Yugrakh has received research support from Teva.
Paul P. Yeung, MD, PhD	No disclosure on file
Xiaoping Ning (Teva pharmaceuticals)	Ms. Ning has received personal compensation for serving as an employee of Teva Pharmaceutical . Ms. Ning has received personal compensation for serving as an employee of Teva Pharmaceutical.

��ɫ��

��ɫ��